Jennifer Woyach is a Hematology physician affiliated with The Ohio State University. OpenAlex indexes 622 publications with 18,468 citations (h-index 62); ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-3196Provider last certified this registry record 25 Feb 2026.
Clinical trials
- Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Sponsor: Jennifer Woyach
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Sponsor: Aseel Alsouqi
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20253 payments
- ABBVIE INC.Program year20255 payments
- ABBVIE INC.Program year20248 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor76.5%Calquence34%Brukinsa30%Jaypirca20%Imbruvica15%Part D<11 patientsBCL-2 Inhibitor23.5%Venclexta100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- OSU as a Network Lead Academic Participating Site for the NCI NCTN
Ohio State University
FY2026$1,015,102UG1CA233331 - Project 03: Leukemia and Hematological Malignancies Research (LHM)
Ohio State University
FY2026$58,203P30CA016058
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
New England Journal of Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ernest Mazzaferri, MD
The Ohio State University
Steven Gabbe, MD
The Ohio State University
Carl Leier, MD
The Ohio State University
Anahita Adeli, MD
The Ohio State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”